Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.55 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | GLB1 | P16278 | 1/20 | 0.55 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12334740 | 1.00 | GBA1 (0.55) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL403895 | 1.00 | GBA1 (0.55) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL26268116 | 1.00 | GBA1 (0.55) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL10179391 | 0.85 | — | — | |
| SCHEMBL3196556 | 0.85 | — | — | |
| SCHEMBL4445650 | 0.79 | GABRR1 (0.43) | — | |
| SCHEMBL22160590 | 0.79 | GABRR1 (0.43) | — | |
| SCHEMBL13221050 | 0.79 | GABRR1 (0.43) | — | |
| SCHEMBL6335676 | 0.79 | GABRR1 (0.43) | — | |
| SCHEMBL2811192 | 0.79 | GABRR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | GBA1 135/4885FUCA1 42/4885GLA 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.